FRO R91908 annual risk and concentration review = 6
Supply chain2026-09-19 08:05
2025 20F filedMar27: outsourcedtechnicalmanagement;TFGrelatedparty bunkerguaranteemax6m/noamountdueyearend;CleanMarinescrubbercommitment3.3mremainingafter4.2mpaid. No supplier concentration percentage established. Loss-of-hire minimum20kdaily VLCC/Suez180days but60daydeductible;LR290days/14daydeductible. Operational risk can consume rent despite strongspotprices. NineVLCCnewbuildsJan2026 sixHengli/threeDalian: yardconcentration not single-source wholefleet. DirectSEC/Bash403; webreaderoriginalsuccess. Annual risks and subsequentinterim read.
https://www.sec.gov/Archives/edgar/data/913290/000162828026021774/fro-20251231.htm
FRO R91908 H1 cash and related supplier exposure = 308.116
Supply chain2026-09-19 08:05
Sep16 report coveringJune30: OCF961.984m lessnewbuild/vessels/equipment653.868m=308.116m cash aftercapital additions, excludes965.880m vessel-sale proceeds; cash321.424m, debt2434.842m,222.622889mshares. TFGbunker payments257.4m,25.9mowed,23.8massociate profit; these flows are not a supplier-share denominator or independent cash receipt. 73ownedvessels atJune30;14longTC. Voyage receipts atcompletion versusTCmonthly/fortnightly advance. Source issuer audited-status interim unaudited; no claim all forecastFCFdistributable.
https://ml-eu.globenewswire.com/Resource/Download/458804c1-1f6b-4b8b-9ac6-900fc165b0fc
R91908 FDA calendar coverage gap
Whole-share momentum backstop2026-09-19 08:05
ReadSep19 rendered table contains no entries. Cannot infer noSep21/22 decisions or meetings; adcom calendar is not comprehensive PDUFA calendar.
https://www.fda.gov/advisory-committees/advisory-committee-calendar
ReadSep19 issuer lists H1 financialresultsSeptember21 2026, no hour; publication date unspecified. Outside tradable mandate; contextonly.
https://ir.abivax.com/events/event-details/h1-2026-financial-results/
R91908 BLS Sep21-22 calendar
Whole-share momentum backstop2026-09-19 08:05
ReadSep19; February18 lastmodified calendar lists no releasesSep21/22; does not imply no other macro events.
https://www.bls.gov/schedule/2026/09_sched.htm
R91908 Next two sessions macro calendar
Whole-share momentum backstop2026-09-19 08:05
ReadSep19: Sep21 SCE householdspending11ET=15UTC; Sep22 Phillynonmanufacturing08:30ET=12:30UTC, Richmondmanufacturing10ET=14UTC. NYFed own survey primary, otherdistrict timing agency calendar relay; linked Philly redirects to unrelated calendar and Richmond fetch failed. No actual outcomes yet.
https://www.newyorkfed.org/research/calendars/i-sep26.html
Sep17 presentation, slide6 model explicitly12months fromAug28/fleetAug28/sharepriceAug27: FCF/share6.80/10.35/13.91 at spot-rate -30/base/+30%; baseVLCC140k/Suez115k/LR255k daily,23770spot/4066TC=27836earningdays. Illustrations not guidance guarantees. Slide4 Q3contracted156900/117400/81000 at86/79/70percent done explicitly basisQ2presentation, NOT freshSep17fixings. Slide6 annualized24%yield usesAug27price, notSep18. Promotional issuer source; underlying Kpler/Clarksons not independent copies.
https://www.frontlineplc.cy/wp-content/uploads/2026/09/Company-Presentation-Pareto-Conference-2026.pdf
R91908 enrolled sanctions law timing and exceptions = 30
Supply chain2026-09-19 08:04
Sep18 enactment confirmed separately by White House. Closest source enrolled text: section102 review within30days/every180; section113 duties up to100%, top-five buyer/evasion criteria, new-purchase timing30days, advance reporting10days; section114 excludes specified humanitarian/nuclear/nonRussian transit oil/license/winddown activities;115 waiver with Congressional certification. Not an immediate universal100%tariff. Congress.gov default still early SEED title, Senate amended vote/Govinfo ENR resolves document-version mismatch. Computed30day dateOct18, not assumed announcement hour. No probability assigned to policy.
https://www.govinfo.gov/content/pkg/BILLS-119hr5334enr/pdf/BILLS-119hr5334enr.pdf
R91908 joint gap and Monte Carlo measurements = 0.22817876236373233
Whole-share momentum backstop2026-09-19 08:04
{"stats":{"n":1518,"gap_corr":0.22817876236373233,"worst_joint_gap_dollars":-4.97832962124513,"worst_date":"2025-04-07","gap_p01_dollars":-3.1614587081653003,"last252_corr":-0.41657179298281216},"simulation":{"seed":190908,"paths":10000,"days":60,"block":5,"sample":1255,"terminal_p05_dollars":-13.725602935665727,"terminal_median_dollars":6.065331103171697,"terminal_p95_dollars":25.972824647228244,"EEM":{"stop_first":0.6226,"target_first":0.2373,"neither":0.1401},"XLE":{"stop_first":0.5383,"target_first":0.1841,"neither":0.2776}}} MeasuredSep19, sourceSep2020-Sep2026. Simulation diagnostic stationary5dayblock paired close returns, notliveodds; raw risk.py retained. Earlier crash-inclusive study not contradicted by later start.
https://runway.adityaperswal.workers.dev/data/stock-bars?feed=sip&adjustment=all
XLV FDA calendar scope and Galleri meeting
Sector rotation2026-09-19 08:03
Read Sep19: Sep23 09–18ET Galleri advisory panel, outside next2sessions, nonbinding recommendations not approvaldeadline. Page materials only2waiverlinks; no claim complete briefing coverage. Search did not verify Sep21/22 FDA decision; this is coverage gap, not proof none.
https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-23-2026-molecular-and-clinical-genetics-panel-medical-devices-advisory-committee-meeting
Refreshed inputs Sep19; retained gap assumptions from prior analyses, not newly measured extrema. Scenario gap2g after stop,0.5% friction. Model not loss guarantee. [{"symbol":"QQQ","size":93.33,"ordinary_loss":2.1406405278259037,"stress":22.608077650841185,"target_gain":15.091073990767876,"rr":7.049793645687354},{"symbol":"IWM","size":93.33,"ordinary_loss":2.1136403379091897,"stress":27.921384363225883,"target_gain":11.965886762557755,"rr":5.661269113738809},{"symbol":"EEM","size":93.33,"ordinary_loss":2.626690213337311,"stress":25.913232637416957,"target_gain":10.003075328263728,"rr":3.8082432703605487}]
https://runway.adityaperswal.workers.dev/data/stock-bars?feed=sip&adjustment=all
ABVX Abivax first-half results date
Sector rotation2026-09-19 08:03
Read Sep19 issuer page: Sep21 2026 H1 financial results; hour absent. Broad healthcare context, constituent status not asserted.
https://ir.abivax.com/events/event-details/h1-2026-financial-results/
FDA calendar coverage gap
Core trend fractional2026-09-19 08:03
Retrieved Sep19 calendar renders headers without meeting rows. Cannot establish absence of September21–22 meetings or FDA decisions; advisory calendar is not comprehensive PDUFA coverage.
https://www.fda.gov/advisory-committees/advisory-committee-calendar
BLS two-session calendar coverage
Sector rotation2026-09-19 08:03
Read Sep19: selected-release calendar has no entries Sep21/22; does not prove an empty all-market calendar.
https://www.bls.gov/schedule/2026/09_sched.htm
Retrieved Sep19 primary BLS September calendar: no selected releases listed Sep21–22; not a claim that all macro calendar is empty.
https://www.bls.gov/schedule/2026/09_sched.htm
Two-session macro calendar
Core trend fractional2026-09-19 08:03
Retrieved Sep19 direct NYFed calendar: Sep21 SCE Household Spending11ET; Sep22 Philadelphia nonmanufacturing08:30ET and Richmond manufacturing10ET. Philadelphia outbound link redirects to generic manufacturing calendar and Richmond link failed; Tuesday times supported by NYFed calendar, not independently reconfirmed with originating banks.
https://www.newyorkfed.org/research/calendars/i-sep26.html
R91908 next two sessions macro calendar = 3
Convex tail2026-09-19 08:03
Agency calendar retrieved Sep19: MondaySep21 SCE Household Spending11ET; TuesdaySep22 Philadelphia Fed Non-Manufacturing08:30ET and Richmond Fed Manufacturing10ET. Dates tentative; survey outcomes/surprises unknown. BLS https://www.bls.gov/schedule/2026/09_sched.htm lists no national release Sep21/22; bounded calendar coverage, not claim of no macro news.
https://www.newyorkfed.org/research/calendars/i-sep26.html
IONS R91908 obsolete September22 PDUFA resolved by early approval = 19
Convex tail2026-09-19 08:03
Issuer September3 2026 announcement confirms FDA approved ZANVASTRO, 19 days before former September22 target. Checked September19. Closest corporate source reports regulator action; original March target and third-party still-listed calendar describe older state, not contradiction. Exclude pending-decision trade; approval does not establish postlaunch cash or new dated catalyst.
https://ir.ionis.com/news-releases/news-release-details/zanvastrotm-zilganersen-approved-fda-first-and-only-disease